Tech Company Financing Transactions
AATec Medical Funding Round
On 7/17/2023, AATec Medical raised $3 million in Seed investment from private investors.
Transaction Overview
Company Name
Announced On
7/17/2023
Transaction Type
Venture Equity
Amount
$3,019,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to scale up its technology, expand the team and prepare for clinical studies expected to start in 2024.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Friedenheimer Brücke 20 (c/o nutrion offices)
München, 80639
DE
München, 80639
DE
Phone
Undisclosed
Website
Email Address
Overview
AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. The first product candidate is a novel AAT formulation for inhalation to treat emerging inflammatory diseases of the lung and respiratory virus infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rüdiger Jankowsky
Chief Marketing Officer
Michael Strassmair
Chief Scientific Officer
Manfred Stangl
Browse more venture capital transactions:
Prev: 7/17/2023: MODIFI venture capital transaction
Next: 7/17/2023: Runway venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs